Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells

Background <p>Optimizing T cell activation strength is emerging as a critical factor in improving adoptive cellular therapy (ACT). We previously reported that neoantigen-specific T cell receptor (TCR) clonotypes from a patient with metastatic melanoma exhibited enhanced resilience to repeated stimulation when initially activated at moderate levels.</p> Methods <p>Building on these observations, we applied transient, low-dose MEK inhibition (MEKi) to fine-tune…